Project Grant F30CA294611
Award Date 1/10/26
Completion Date 9/9/28
Dollars Obligated $109K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Cleveland, OH 44106, USA
Similar Awards
- This $997,410 Project Grant award from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394) aims to develop non-invasive MRI-based techniques to detect and differentiate between the invasive neuronal (NEU) and glycolytic/plurimetabolic (GPM) subtypes of high-grade glioma brain tumors. The project leverages recent discoveries about these tumor subtypes' distinct microstructural, metabolic, and synapse profiles to enable more comprehensive tumor...
- This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $162,486 to Case Western Reserve University to study translation regulation in glioblastoma stem-like cells (GSCs) and their adaptation to hypoxic tumor environments. The research aims to gain a better understanding of GSC biology and the post-transcriptional regulatory mechanisms that enable them to thrive in both low and normal oxygen conditions, promoting glioblastoma tumor growth....
- This $3,155,815 Project Grant award from the National Cancer Institute (NCI), under the CFDA 93.394 Cancer Detection and Diagnosis Research program, supports research to develop advanced magnetic resonance imaging techniques for non-invasive measurement of glutamate metabolism in glioblastoma brain tumors. The primary awardee is Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare System, which will leverage its expertise in medical research, imaging technologies, and...
- This federal Project Grant award of $677,801, provided by the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports research at Yale University to develop a non-invasive magnetic resonance imaging (MRI) technique called Deuterium Metabolic Imaging (DMI) for detecting and monitoring disease progression in patients with glioblastoma, an aggressive brain tumor. The key objectives are to: 1) validate the specificity of DMI for detecting active...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $151,856 to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University to conduct research on the relationship between the hyper-thrombotic state and immunosuppression in glioblastoma (GBM), the most common primary malignant brain tumor. The research aims to: 1) investigate how GBM induces platelet hyperactivity and its impact on tumor growth, and 2)...
- The National Cancer Institute (NCI), part of the U.S. Department of Health and Human Services, awarded a $677,998 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to The Medical College of Wisconsin, Inc. (MCW). The project aims to externally validate and integrate radiopathomic models developed using autopsy and biopsy samples to better delineate the true extent of glioma tumors and identify microscopic infiltrating tumor cells. The research will refine...
- This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $147,486 to Case Western Reserve University to develop a "Pathologically Interpretable Computational Imaging Predictor for Response to Total Neoadjuvant Treatment in Rectal Cancers". The project aims to apply deep learning techniques to routinely acquired MRI scans to accurately identify rectal cancer patients who exhibit a complete clinical response to neoadjuvant therapy,...
- This $638,697 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program supports research by the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University (CCLCM) to investigate the role of the SMARCA5 protein in the development and progression of glioblastoma, an aggressive type of brain cancer. The goal of the research is...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $2,820,337.00 to the Regents of the University of Michigan to develop new methods to directly measure metabolic pathway activity in mouse models and patients with glioblastomas (GBMs), which are deadly and incurable brain cancers. The goal is to identify optimal metabolic treatment strategies for GBM patients by evaluating the safety, on-target activity, and potential efficacy of new...
- This Project Grant award of $134,574.00 from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research to investigate mechanisms underlying brain tumor microenvironment-specific suppression of anti-tumor immunity mediated by aberrant epidermal growth factor receptor (EGFR) signaling in glioblastoma (GBM). The research leverages a novel EGFR-activated immunocompetent murine glioma model to determine the impact of aberrant EGFR signaling and tumor-programmed...